Lymphatic Metastasis Predicts Better Response to Nivolumab in Recurrent or Metastatic Gastric Cancer: Insights from Tumor-Draining Lymph Node Immunity and Long-Term Outcomes.

Oncology · 2026 · PMC12790426 · PMID 41343455

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Both ORR and DCR were numerically higher in the HER2-positive group (8.7% and 43.4%) than in the HER2-negative group (7.4% and 33.3%), but the differences did not reach statistical significance ( Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.